Goserelin Acetate Patent Expiration
Goserelin Acetate was first introduced by Tersera Therapeutics Llc
Goserelin Acetate Patents
Given below is the list of patents protecting Goserelin Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zoladex | US7118552 | Automatically operable safety shield system for syringes |
Apr 13, 2022
(Expired) | Tersera |
| Zoladex | US7220247 | Automatically operable safety shield system for syringes |
Apr 09, 2022
(Expired) | Tersera |
| Zoladex | US7500964 | Automatically operable safety shield system for syringes |
Feb 26, 2021
(Expired) | Tersera |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Goserelin Acetate's patents.
Latest Legal Activities on Goserelin Acetate's Patents
Given below is the list recent legal activities going on the following patents of Goserelin Acetate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Aug, 2020 | US7500964 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 16 Oct, 2018 | US7220247 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Mar, 2018 | US7118552 |
| Email Notification Critical
| 07 Jun, 2017 | US7500964 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 07 Jun, 2017 | US7500964 |
| Correspondence Address Change Critical
| 05 Jun, 2017 | US7500964 |
| Electronic Review Critical
| 30 May, 2017 | US7500964 |
| Email Notification Critical
| 26 May, 2017 | US7500964 |
| Mail Pre-Exam Notice | 26 May, 2017 | US7500964 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 24 May, 2017 | US7118552 |
Goserelin Acetate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Goserelin Acetate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer | Genentech, Inc. | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma | Manish Patel | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients | Mayo Clinic | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | City of Hope Medical Center | NA |
ACTIVE NOT RECRUITING
(Mar 1, 2026)
| PHASE2 |